article thumbnail

Nektar lifted by Merck alliance for bempeg, new trial funding

pharmaphorum

The post Nektar lifted by Merck alliance for bempeg, new trial funding appeared first on. The deals with Merck and SFJ are an endorsement of the bempeg programme after initial results from mid-stage studies with the drug generated some lacklustre results in melanoma and triple negative breast cancer (TNBC).

article thumbnail

Government of Canada invests in clinical trial development in Canada through the Clinical Trials Fund

Pharma in Brief

On June 22, 2022, the Canadian Institutes of Health Research ( CIHR ) announced the launch of the Clinical Trials Fund ( CTF ), which will inject funding into Canada’s clinical trials environment. The Clinical Trials Fund.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Reducing lung transplant rejection aim of clinical trial funded with $22 million grant

Scienmag

Louis and Massachusetts General Hospital/Harvard Medical School in Boston have received a seven-year, $22 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to help lead a multicenter clinical trial evaluating whether a novel immunosuppressant can […].

article thumbnail

STAT+: ‘A blind eye’: NIH fails to ensure clinical trial results are reported and funds researchers who don’t file results

STAT News

National Institutes of Health failed to ensure that results of roughly half of clinical trials funded by the agency — both those conducted by its own scientists and outside researchers — were reported to a federal database during a recent two-year period, a new government review has found.

article thumbnail

Boston University taps Shimmer wearables for brain studies

Outsourcing Pharma

The trials, funded by the American Heart Association, will harness the companyâs Verisense wearable sensor platform to examine brain-heart health links.

article thumbnail

Oral immunotherapy induces remission of peanut allergy in some young children

Scienmag

A clinical trial funded by the National Institutes of Health has found that giving peanut oral immunotherapy to highly peanut-allergic children ages 1 to 3 years safely desensitized most of them to peanut and induced remission of peanut allergy in one-fifth. The immunotherapy consisted of a daily oral dose of peanut flour for 2.5

article thumbnail

Synedgen Initiates Clinical Trial Assessing Combination of SynePure and Catasyn for the Treatment of Partial Thickness Burns

BioTech 365

Synedgen Initiates Clinical Trial Assessing Combination of SynePure and Catasyn for the Treatment of Partial Thickness Burns Synedgen Initiates Clinical Trial Assessing Combination of SynePure and Catasyn for the Treatment of Partial Thickness Burns – Trial funded by Defense Health … Continue reading →